The 250-square-metre facility in the UAE will manufacture hormone medicines, supporting local pharmaceutical production and the country’s drug security ambitions.
UAE-based PODTECH has completed a prefabricated modular pharmaceutical manufacturing facility for Bioventure Healthcare, a subsidiary of Mubadala Bio, expanding the company’s local production capacity for hormone medicines.
The facility comprises 14 PODULE™ modular units covering 250 square metres and is designed for oral solid dosage hormone medicines. It includes ISO 8-classified cleanrooms, quality control laboratories, a microbiology lab with sterility testing capabilities, and dedicated packaging and containment systems.
PODTECH manufactured the units at its UAE factory, conducted factory acceptance testing and installed them on-site using a plug-and-play approach. Its scope included design, engineering, mechanical, electrical and plumbing systems, heating, ventilation and air conditioning, and validation. The project was delivered within months, according to the company.
The project comes as Mubadala Bio expands local production of hormone and high-potency medicines, with the aim of strengthening national drug security and reducing reliance on imports.
PODTECH says its prefabricated modular approach can reduce project schedules by up to 50% compared with traditional pharmaceutical factory construction, by moving much of the construction and testing off-site.
Founded in 2023, PODTECH manufactures prefabricated, pre-validated modular facilities for pharmaceutical, biotechnology, diagnostics and other advanced manufacturing applications, serving markets across the GCC and Asia-Pacific.
Source: PODTECH
